07:00 , Oct 12, 2015 |  BC Week In Review  |  Clinical News

Anti-HER2-ADC: Interim Phase I data

Interim data from 12 patients with locally advanced or metastatic solid tumors in the dose-escalation part 1 of the 2-part, open-label, European Phase I SYD985.001 trial showed that 0.3, 0.6, 1.2 and 2.4 mg/kg doses...
08:00 , Dec 15, 2014 |  BC Week In Review  |  Clinical News

Anti-HER2-ADC: Phase I started

Synthon began a 2-part, open-label, international Phase I trial of IV SYD985 every 3 weeks in about 76 patients with locally advanced or metastatic solid tumors. The dose-escalation part will test SYD985 in any solid...
07:00 , May 16, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer DNA In vitro and mouse studies suggest prodrugs of the duocarmycin family of DNA-alkylating agents could help treat cancer. In...
08:00 , Feb 11, 2013 |  BC Week In Review  |  Clinical News

Synthon preclinical data

In mouse xenograft models of epidermal growth factor receptor 2 ( EGFR2 ; HER2 ; ErbB2 ; neu)-positive breast cancer and non-small cell lung cancer (NSCLC), Synthon's anti-HER2-ADC induced complete tumor remission, whereas trastuzumab alone...